Abu Lila AS - Search Results

1

Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.

Shimizu T, Abu Lila AS, Nishio M, Doi Y, Ando H, Ukawa M, Ishima Y, Ishida T. Shimizu T, et al. Among authors: abu lila as. Cancer Sci. 2017 Sep;108(9):1864-1869. doi: 10.1111/cas.13305. Epub 2017 Jul 14. Cancer Sci. 2017. PMID: 28643902 Free PMC article.

2

Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.

Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Abu-Lila A, et al. J Control Release. 2009 Feb 20;134(1):18-25. doi: 10.1016/j.jconrel.2008.10.018. Epub 2008 Nov 5. J Control Release. 2009. PMID: 19010364

3

Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.

Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Abu Lila AS, et al. J Control Release. 2009 Jul 1;137(1):8-14. doi: 10.1016/j.jconrel.2009.02.023. Epub 2009 Mar 12. J Control Release. 2009. PMID: 19285528

4

Recent advances in tumor vasculature targeting using liposomal drug delivery systems.

Abu Lila AS, Ishida T, Kiwada H. Abu Lila AS, et al. Expert Opin Drug Deliv. 2009 Dec;6(12):1297-309. doi: 10.1517/17425240903289928. Expert Opin Drug Deliv. 2009. PMID: 19780711 Review.

5

Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.

Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H. Abu Lila AS, et al. J Control Release. 2010 Mar 3;142(2):167-73. doi: 10.1016/j.jconrel.2009.10.020. Epub 2009 Oct 25. J Control Release. 2010. PMID: 19861140

6

Targeting anticancer drugs to tumor vasculature using cationic liposomes.

Abu Lila AS, Ishida T, Kiwada H. Abu Lila AS, et al. Pharm Res. 2010 Jul;27(7):1171-83. doi: 10.1007/s11095-010-0110-1. Epub 2010 Mar 24. Pharm Res. 2010. PMID: 20333455 Review.

7

A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. Nakamura K, et al. Among authors: abu lila as. Mol Ther. 2011 Nov;19(11):2040-7. doi: 10.1038/mt.2011.174. Epub 2011 Aug 30. Mol Ther. 2011. PMID: 21878904 Free PMC article.

8

Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?

Abu Lila AS, Okada T, Doi Y, Ichihara M, Ishida T, Kiwada H. Abu Lila AS, et al. Int J Pharm. 2012 Apr 15;426(1-2):263-270. doi: 10.1016/j.ijpharm.2012.01.046. Epub 2012 Jan 30. Int J Pharm. 2012. PMID: 22310465

9

Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.

Abu Lila AS, Matsumoto H, Doi Y, Nakamura H, Ishida T, Kiwada H. Abu Lila AS, et al. Eur J Pharm Biopharm. 2012 Aug;81(3):524-31. doi: 10.1016/j.ejpb.2012.04.010. Epub 2012 Apr 25. Eur J Pharm Biopharm. 2012. PMID: 22554766

10

Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.

Abu Lila AS, Eldin NE, Ichihara M, Ishida T, Kiwada H. Abu Lila AS, et al. Int J Pharm. 2012 Nov 15;438(1-2):176-83. doi: 10.1016/j.ijpharm.2012.08.030. Epub 2012 Aug 24. Int J Pharm. 2012. PMID: 22944302

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters